These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15129818)

  • 21. An update on the PDE-5 inhibitors (PDE-5i).
    McCullough AR
    J Androl; 2003; 24(6 Suppl):S52-8. PubMed ID: 14581496
    [No Abstract]   [Full Text] [Related]  

  • 22. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
    Pickard R
    Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
    [No Abstract]   [Full Text] [Related]  

  • 23. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
    Burnett AL
    Urology; 2005 Feb; 65(2):224-30. PubMed ID: 15708027
    [No Abstract]   [Full Text] [Related]  

  • 24. Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification.
    Donatucci C; Eardley I; Buvat J; Gittelman M; Kell P; Segerson T; Homering M; Montorsi F;
    J Sex Med; 2004 Nov; 1(3):301-9. PubMed ID: 16422960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of nitric oxide in erectile dysfunction: implications for medical therapy.
    Burnett AL
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12 Suppl 4):53-62. PubMed ID: 17170606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epimedium brevicornum Maxim extract relaxes rabbit corpus cavernosum through multitargets on nitric oxide/cyclic guanosine monophosphate signaling pathway.
    Chiu JH; Chen KK; Chien TM; Chiou WF; Chen CC; Wang JY; Lui WY; Wu CW
    Int J Impot Res; 2006; 18(4):335-42. PubMed ID: 16395327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
    Hutter AM
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I1-2. PubMed ID: 15115188
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacology of erectile dysfunction in man.
    Cirino G; Fusco F; Imbimbo C; Mirone V
    Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [7 years PDE-5 inhibitor for therapy of erection disorders].
    Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
    Lobo JR; Nehra A
    Urol Clin North Am; 2005 Nov; 32(4):447-55, vi. PubMed ID: 16291036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current oral treatments for erectile dysfunction.
    Kalsi JS; Cellek S; Muneer A; Kell PD; Ralph DJ; Minhas S
    Expert Opin Pharmacother; 2002 Nov; 3(11):1613-29. PubMed ID: 12437495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relaxation effect of nitric oxide-donor on diabetic penile smooth muscle in vitro.
    Taher A; Birowo P; Kamil ST; Shahab N
    Clin Hemorheol Microcirc; 2000; 23(2-4):277-81. PubMed ID: 11321451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent insights into androgen action on the anatomical and physiological substrate of penile erection.
    Gooren LJ; Saad F
    Asian J Androl; 2006 Jan; 8(1):3-9. PubMed ID: 16372114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular system as a 'core' of sexual life.
    El-Sakka AI
    Expert Opin Pharmacother; 2005 Oct; 6(13):2223-30. PubMed ID: 16218883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
    Aversa A; Bruzziches R; Pili M; Spera G
    Curr Pharm Des; 2006; 12(27):3467-84. PubMed ID: 17017940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
    Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
    Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Montorsi F; Briganti A; Salonia A; Montorsi P; Rigatti P
    Curr Opin Urol; 2004 Nov; 14(6):357-9. PubMed ID: 15626879
    [No Abstract]   [Full Text] [Related]  

  • 40. Nitric oxide and penile erectile function.
    Toda N; Ayajiki K; Okamura T
    Pharmacol Ther; 2005 May; 106(2):233-66. PubMed ID: 15866322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.